← Back to Search

CAR T-cell Therapy

CC-95266 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Juno Therapeutics, a Subsidiary of Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Age ≥ 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years after cc-95266 infusion
Awards & highlights

Study Summary

This trial is testing a new drug for people with multiple myeloma who haven't responded to other treatments. They want to see if it's safe and if it works.

Who is the study for?
This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment. They must have had at least three prior treatments (or one to three for a specific group) and show signs of disease progression. Good physical health and organ function are required, but those with central nervous system involvement, certain medical histories, or active autoimmune diseases can't join.Check my eligibility
What is being tested?
The study tests the safety and initial effectiveness of CC-95266 in patients whose multiple myeloma has relapsed or is resistant to treatment. It also involves other drugs like Cyclophosphamide, Fludarabine, and Bendamustine as part of the therapy regimen.See study design
What are the potential side effects?
Potential side effects may include nausea, hair loss from Cyclophosphamide; immune system suppression from Fludarabine; skin reactions and possible kidney damage from Bendamustine; plus any unknown risks associated with the new drug CC-95266.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years after cc-95266 infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years after cc-95266 infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD)
Number of participants with Adverse Events (AEs)
Number of participants with Dose Limiting Toxicities (DLTs)
+2 more
Secondary outcome measures
Complete response rate (CRR)
Duration of complete response (DOCR)
Duration of response (DOR)
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Administration of CC-95266Experimental Treatment4 Interventions
Subjects will receive CC-95266 after completion of lymphodepleting (LD) chemotherapy (fludarabine and cyclophosphamide)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3770
Fludarabine
2012
Completed Phase 3
~1080
Bendamustine
2015
Completed Phase 3
~2950

Find a Location

Who is running the clinical trial?

Juno Therapeutics, a Subsidiary of CelgeneLead Sponsor
11 Previous Clinical Trials
1,274 Total Patients Enrolled
3 Trials studying Multiple Myeloma
323 Patients Enrolled for Multiple Myeloma
Allison Kaeding, MDStudy DirectorBristol-Myers Squibb
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,510 Previous Clinical Trials
3,370,945 Total Patients Enrolled
73 Trials studying Multiple Myeloma
25,725 Patients Enrolled for Multiple Myeloma

Media Library

CC-95266 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04674813 — Phase 1
Multiple Myeloma Research Study Groups: Administration of CC-95266
Multiple Myeloma Clinical Trial 2023: CC-95266 Highlights & Side Effects. Trial Name: NCT04674813 — Phase 1
CC-95266 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04674813 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any prior research regarding the efficacy of CC-95266?

"Currently, 889 CC-95266 clinical trials are in progress with 161 being Phase 3. Philadelphia, Pennsylvania is the primary trial site for this study; however, 28446 different locations across the world have studies testing CC-95266."

Answered by AI

How many participants is the clinical trial limited to?

"Juno Therapeutics, a Subsidiary of Celgene, is responsible for the management and execution of this clinical trial. To fully commence operations 77 participants that satisfy the criteria are necessary; Memorial Sloan Kettering Cancer Center in Duarte, California and City Of Hope in Dallas, Texas will be two of its sites."

Answered by AI

How many venues are participating in this trial's implementation?

"Memorial Sloan Kettering Cancer Center in Duarte, California, City Of Hope in Dallas, Texas and Southwestern Medical Center- Harold C Simmons Comprehensive Cancer Center in Denver, Colorado are the three main sites where this trial is being conducted. Additionally, there are 14 other medical centres that participate."

Answered by AI

What is CC-95266 typically prescribed for?

"CC-95266 is the go-to medication for managing symptoms of multiple sclerosis. This drug also shows efficacy in treating mixed-cell type lymphoma, leukemia, myelocytic acute and retinoblastoma cases."

Answered by AI

Is this project actively seeking participants?

"Affirmative. According to the clinicaltrials.gov database, enrollment for this research is currently underway and began on February 24th 2021. The study requires 77 volunteers from 14 different healthcare institutions and was last modified on October 11th 2022."

Answered by AI

Has CC-95266 received the necessary regulatory clearances for use?

"As a Phase 1 trial, the safety of CC-95266 is graded at an estimated 1 since there are few data points validating its efficacy and security."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
2021. "A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04674813.
~42 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top